[1] Jylhävä J, Nevalainen T, Marttila S, Jylhä M, Hervonen A, Hurme M. Characterization of the role of distinct plasma cell-free DNA species in age-associated inflammation and frailty. Aging Cell. 2013;12(3):388-397. doi:10.1111/acel.12058
[2] Bacalini MG, D’Aquila P, Marasco E, et al. The methylation of nuclear and mitochondrial DNA in ageing phenotypes and longevity. Mech Ageing Dev. 2017;165:156–161. doi:10.1016/j.mad.2017.01.006
[3] Puntmann VO, Taylor PC, Mayr M. Coupling vascular and myocardial inflammatory injury into a common phenotype of cardiovascular dysfunction: systemic inflammation and aging - a mini-review. Gerontology. 2011;57(4):295-303. doi:10.1159/000316577
[4] Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016,16(11):676-689. doi:10.1038/nri.2016.95
[5] Cayrol C, Girard JP. Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine. Cytokine. 2022, 156:155891. doi:10.1016/j.cyto.2022.155891
[6] Magat JM, Thomas JL, Dumouchel JP, Murray F, Li WX, Li J. Endogenous IL-33 and Its Autoamplification of IL-33/ST2 Pathway Play an Important Role in Asthma. J Immunol. 2020;204(6):1592-1597. doi:10.4049/jimmunol.1900690
[7] Pollheimer J, Bodin J, Sundnes O, et al. Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells. Arterioscler Thromb Vasc Biol. 2013;33(2):e47-e55. doi:10.1161/ATVBAHA.112.253427
[8] Wang YM, Shaw K, Zhang GY, et al. Interleukin-33 Exacerbates IgA Glomerulonephritis in Transgenic Mice Overexpressing B Cell Activating Factor. J Am Soc Nephrol. 2022;33(5):966-984. doi:10.1681/ASN.2021081145
[9] Zhuang X, Zhan B, Jia Y, et al. IL-33 in the basolateral amygdala integrates neuroinflammation into anxiogenic circuits via modulating BDNF expression. Brain Behav Immun. 2022;102:98-109. doi:10.1016/j.bbi.2022.02.019
[10] Homsak E, Gruson D. Soluble ST2: A complex and diverse role in several diseases. Clin Chim Acta. 2020, 507:75-87. doi:10.1016/j.cca.2020.04.011
[11] Dudek M, Kałużna-Oleksy M, Migaj J, Straburzyńska-Migaj E. Clinical value of soluble ST2 in cardiology. Adv Clin Exp Med. 2020;29(10):1205-1210. doi:10.17219/acem/126049
[12] Demyanets S, Kaun C, Pentz R, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. 2013;60:16-26. doi:10.1016/j.yjmcc.2013.03.020
[13] Zhang J, Chen Z, Ma M, He Y. Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance. Front Cardiovasc Med. 2022;9:924461. Published 2022 Sep 26. doi:10.3389/fcvm.2022.924461
[14] Altara R, Ghali R, Mallat Z, Cataliotti A, Booz GW, Zouein FA. Conflicting vascular and metabolic impact of the IL-33/sST2 axis. Cardiovasc Res. 2018;114(12):1578-1594. doi:10.1093/cvr/cvy166
[15] Hughes MF, Appelbaum S, Havulinna AS, et al. ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality. Heart. 2014, 100(21):1715-1721. doi:10.1136/heartjnl-2014-305968
[16] Yue X, Yang X, Lin X, et al. Rnd3 haploinsufficient mice are predisposed to hemodynamic stress and develop apoptotic cardiomyopathy with heart failure. Cell Death Dis. 2014, 5: e1284. doi:10.1038/cddis.2014.235
[17] Yang X, Wang T, Lin X, et al. Genetic deletion of Rnd3/RhoE results in mouse heart calcium leakage through upregulation of protein kinase A signaling. Circ Res. 2015, 116: e1-e10. doi:10.1161/CIRCRESAHA.116.304940
[18] Dai Y, Song J, Li W, et al. RhoE Fine-Tunes Inflammatory Response in Myocardial Infarction. Circulation. 2019, 139:1185-98. doi:10.1161/CIRCULATIONAHA.118.033700
[19] Zhang Y, Cao Y, Zheng R, et al. Fibroblast-specific activation of Rnd3 protects against cardiac remodeling in diabetic cardiomyopathy via suppression of Notch and TGF-β signaling. Theranostics. 2022;12(17):7250-7266. Published 2022 Oct 17. doi:10.7150/thno.77043
[20] Shao Z, Wang K, Zhang S, et al. Ingenuity pathway analysis of differentially expressed genes involved in signaling pathways and molecular networks in RhoE gene‑edited cardiomyocytes. Int J Mol Med. 2020;46(3):1225-1238. doi:10.3892/ijmm.2020.4661
[21] Demyanets S, Konya V, Kastl SP, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2011;31(9):2080-2089. doi:10.1161/ATVBAHA.111.231431
[22] Paysan L, Piquet L, Saltel F, Moreau V. Rnd3 in Cancer: A Review of the Evidence for Tumor Promoter or Suppressor. Mol Cancer Res. 2016;14(11):1033-1044. doi:10.1158/1541-7786.MCR-16-0164
[23] Jie W, Andrade KC, Lin X, Yang X, Yue X, Chang J. Pathophysiological Functions of Rnd3/RhoE. Compr Physiol. 2015;6(1):169-186. doi:10.1002/cphy.c150018
[24] Wu N, Zheng F, Li N, et al. RND3 attenuates oxidative stress and vascular remodeling in spontaneously hypertensive rat via inhibiting ROCK1 signaling. Redox Biol. 2021,48:102204. doi:10.1016/j.redox.2021.102204
[25] Breslin JW, Daines DA, Doggett TM, et al. Rnd3 as a Novel Target to Ameliorate Microvascular Leakage. J Am Heart Assoc. 2016;5(4):e003336. doi:10.1161/JAHA.116.003336
[26] Cayrol C, Girard JP. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev. 2018, 281(1):154-168. doi:10.1111/imr.12619
[27] Chan BCL, Lam CWK, Tam LS, Wong CK. IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. Front Immunol. 2019, 10:364. doi:10.3389/fimmu.2019.00364
[28] Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 Axis in Organ Fibrosis. Front Immunol. 2018, 9:2432. doi:10.3389/fimmu.2018.02432
[29] Florens N, Kasam RK, Rudman-Melnick V, Lin SC, Prasad V, Molkentin JD. Interleukin-33 Mediates Cardiomyopathy After Acute Kidney Injury by Signaling to Cardiomyocytes. Circulation. 2023;147(9):746-758. doi:10.1161/CIRCULATIONAHA.122.063014
[30] Wu MX, Wang SH, Xie Y, et al. Interleukin-33 alleviates diabetic cardiomyopathy through regulation of endoplasmic reticulum stress and autophagy via insulin-like growth factor-binding protein 3. J Cell Physiol. 2021, 236(6):4403-4419. 2021;236(6):4403-4419. doi:10.1002/jcp.30158
[31] Mia MM, Cibi DM, Ghani SABA, et al. Loss of Yap/Taz in cardiac fibroblasts attenuates adverse remodelling and improves cardiac function. Cardiovasc Res. 2022,118(7):1785-1804. doi:10.1093/cvr/cvab205
[32] Dandan-Zong, Shen C, Liu X, Liu T, Ou Y, Ouyang R. IL-33/ST2 mediating systemic inflammation and neuroinflammation through NF-kB participated in the neurocognitive impairment in obstructive sleep apnea. Int Immunopharmacol. 2023, 115: 109604. doi:10.1016/j.intimp.2022.109604
[33] Yue X, Lin X, Yang T, et al. Rnd3/RhoE Modulates Hypoxia-Inducible Factor 1α/Vascular Endothelial Growth Factor Signaling by Stabilizing Hypoxia-Inducible Factor 1α and Regulates Responsive Cardiac Angiogenesis. Hypertension. 2016, 67(3):597-605. doi:10.1161/HYPERTENSIONAHA.115.06412
[34] Lotierzo M, Dupuy AM, Kalmanovich E, et al. sST2 as a value-added biomarker in heart failure. Clin Chim Acta. 2020, 501:120-113. doi:10.1016/j.cca.2019.10.029